Free Trial
OTCMKTS:NEVPF

Abliva AB (publ) (NEVPF) Stock Price, News & Analysis

Abliva AB (publ) logo
$0.03 0.00 (0.00%)
As of 11/6/2026

About Abliva AB (publ) Stock (OTCMKTS:NEVPF)

Advanced

Key Stats

Today's Range
$0.03
▼
$0.03
50-Day Range
$0.03
▼
$0.03
52-Week Range
$0.01
▼
$0.04
Volume
N/A
Average Volume
4,445 shs
Market Capitalization
$11.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Abliva AB (publ) is a Swedish biotechnology company focused on developing treatments for primary mitochondrial diseases, a group of rare genetic disorders caused by impaired mitochondrial function. The company’s work centers on therapies intended to address the energy deficiencies and debilitating symptoms associated with these conditions.

Abliva’s lead drug candidate is KL1333, an orally administered therapy being developed for adults with genetically confirmed primary mitochondrial disease. The company has also researched NV354, a potential treatment for mitochondrial diseases involving complex II deficiency, including Leigh syndrome. Its development programs have included clinical and preclinical research conducted in collaboration with international healthcare and research organizations.

The company was formerly known as NeuroVive Pharmaceutical AB and adopted the Abliva name in 2020. Based in Lund, Sweden, Abliva has pursued a global clinical-development strategy for rare diseases and has sought regulatory and commercial partnerships to advance its mitochondrial medicine programs.

AI Generated. May Contain Errors.

Receive NEVPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NEVPF Stock News Headlines

Pharming announces public cash offer to shareholders of Abliva AB
Stillfront Group publ AB (SFRG)
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
IVSXF Investor AB (publ)
Interfox Resources publ AB (IFOX)
Cell Impact publ AB (CELLI)
See More Headlines

NEVPF Stock Analysis - Frequently Asked Questions

Abliva AB (publ)'s stock was trading at $0.0280 at the start of the year. Since then, NEVPF stock has increased by 0.0% and is now trading at $0.0280.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abliva AB (publ) investors own include Arbutus Biopharma (ABUS) and Cloud Peak Energy (CLDPQ).

Company Calendar

Today
11/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:NEVPF
CIK
N/A
Employees
8
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.01 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-117.92%
Return on Assets
-102.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.99
Quick Ratio
7.99

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
1,128.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
1.40

Miscellaneous

Outstanding Shares
403,010,000
Free Float
N/A
Market Cap
$11.28 million
Optionable
Not Optionable
Beta
-1.18
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:NEVPF) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners